BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25910865)

  • 1. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening.
    Stegeman I; van Doorn SC; Mundt MW; Mallant-Hent RC; Bongers E; Elferink MA; Fockens P; Stroobants AK; Bossuyt PM; Dekker E
    Cancer Epidemiol; 2015 Jun; 39(3):388-93. PubMed ID: 25910865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attendance and yield over three rounds of population-based fecal immunochemical test screening.
    Kapidzic A; Grobbee EJ; Hol L; van Roon AH; van Vuuren AJ; Spijker W; Izelaar K; van Ballegooijen M; Kuipers EJ; van Leerdam ME
    Am J Gastroenterol; 2014 Aug; 109(8):1257-64. PubMed ID: 24980879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round.
    Stegeman I; de Wijkerslooth TR; Mallant-Hent RC; de Groot K; Stroobants AK; Fockens P; Mundt M; Bossuyt PM; Dekker E
    BMC Gastroenterol; 2012 Jun; 12():73. PubMed ID: 22713100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
    Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
    Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study.
    Schreuders EH; Grobbee EJ; Nieuwenburg SAV; Kapidzic A; van Roon AHC; van Vuuren AJ; Lansdorp-Vogelaar I; Spijker WWJ; Izelaar K; Bruno MJ; Kuipers EJ; Spaander MCW
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):622-631. PubMed ID: 31196734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained participation, colonoscopy uptake and adenoma detection rates over two rounds of the Tallaght-Trinity College colorectal cancer screening programme with the faecal immunological test.
    McNamara D; Leen R; Seng-Lee C; Shearer N; Crotty P; Neary P; Walsh P; Boran G; O'Morain C
    Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1415-21. PubMed ID: 25244415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.
    Jensen CD; Corley DA; Quinn VP; Doubeni CA; Zauber AG; Lee JK; Zhao WK; Marks AR; Schottinger JE; Ghai NR; Lee AT; Contreras R; Klabunde CN; Quesenberry CP; Levin TR; Mysliwiec PA
    Ann Intern Med; 2016 Apr; 164(7):456-63. PubMed ID: 26811150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
    Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
    Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
    Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
    Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance.
    Kwak MS; Cha JM; Yoon JY; Jeon JW; Shin HP; Joo KR; Lee JI
    J Clin Gastroenterol; 2017 Oct; 51(9):825-830. PubMed ID: 27824639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Participation rate and detection of colorectal neoplasms based on multi-round fecal immunochemical testing for colorectal cancer screening in the Chinese population].
    Li N; Zhou YY; Lu M; Zhang YH; Lu B; Luo CY; Luo JH; Cai J; Chen HD; Dai M
    Zhonghua Zhong Liu Za Zhi; 2023 Dec; 45(12):1041-1050. PubMed ID: 38110312
    [No Abstract]   [Full Text] [Related]  

  • 16. Divergent Long-Term Detection Rates of Proximal and Distal Advanced Neoplasia in Fecal Immunochemical Test Screening Programs: A Retrospective Cohort Study.
    Zorzi M; Hassan C; Capodaglio G; Narne E; Turrin A; Baracco M; Dal Cin A; Fiore A; Martin G; Repici A; Rex D; Rugge M
    Ann Intern Med; 2018 Nov; 169(9):602-609. PubMed ID: 30285055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program.
    Wieten E; de Klerk CM; van der Steen A; Ramakers CR; Kuipers EJ; Hansen BE; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Gastroenterology; 2018 Nov; 155(5):1392-1399.e5. PubMed ID: 30055170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Oral and Upper Gastrointestinal Cancers in Persons With Positive Results From a Fecal Immunochemical Test in a Colorectal Cancer Screening Program.
    van der Vlugt M; Grobbee EJ; Bossuyt PM; Bos ACRK; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1237-1243.e2. PubMed ID: 29427732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of previous non-participants cannot fully compensate for lower participation in a second round of FIT-screening.
    Denters MJ; Deutekom M; Bossuyt PM; van Rijn AF; Fockens P; Dekker E
    Cancer Epidemiol; 2013 Jun; 37(3):330-5. PubMed ID: 23403127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.